If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"","arm_groups":[{"arm_group_label":"Subjects with HIV infection","arm_group_description":"Subjects receiving DTG-based ART regimen and switching to a two-drug regimen containing DTG (lamivudine [3TC] + DTG, DTG + rilpivirine [RPV] and darunavir/ritonavir [DRV/r] +DTG) or other two-drug regimens frequently prescribed from CoRIS will be included.","arm_type":""}],"assignment":"","brief_summary":"DTG is a second-generation integrase strand transfer inhibitor (INSTI) with a high antiviral potency and a good safety profile, when used with nucleoside backbone in treatment-naive subjects. The data from CoRIS have shown that DTG discontinuations due to adverse events (AEs) were lower than those observed for elvitegravir and raltegravir containing regimens. As DTG is one of the preferred antiretroviral agents for initial antiretroviral treatment, larger cohort studies with long-term follow-up are needed to precisely define its overall performance with regard to AEs and tolerability. Thus, this study is designed to assess the use and effectiveness of DTG-based regimens in naive and virologically suppressed antiretroviral therapy (ART)-experienced subjects from CoRIS. CoRIS is an open, multicenter and prospective cohort of human immunodeficiency virus (HIV)-positive adults, naive to antiretroviral treatment. CoRIS collects a minimum dataset which includes Baseline and follow-up socio-demographic, immunological and clinical data including ART medication, with start and stop dates, as well as reasons for drug discontinuation. The persistence, immunological and virological responses of DTG-based regimens in naive and virologically suppressed ART-experienced subjects who initiated first-line antiretroviral regimens from 1st September 2014 to 30th November 2017 from the CoRIS will be evaluated in this study.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Use and effectiveness of dolutegravir-based regimens in naïve and virologically suppressed ART-experienced individuals from the Cohort of the Spanish AIDS Research Network (CoRIS)","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV infections","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 21:31:13","criteria":"Inclusion Criteria: - Antiretroviral-naïve subjects who started ART between 1st September 2014 and 30th November 2017 with a DTG-based regimen or others frequently prescribed as first-line. - Virologically suppressed ART experienced individuals switching to a two-drug regimen containing DTG from 1st September 2014 to 30th November 2017. - Subjects aged >=18 years Exclusion Criteria: - Subjects with no follow-up after switching to a two-drug regimen containing DTG - Subjects with no follow-up after initiation of ART","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 4","display_phase_internal":"PHASE_4","display_status":"Ongoing","display_status_internal":"RECSTATUS_O_ONGOING","endpoint":"","enrollment":"1000","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"None","id":"6423e501-f8a6-5e4d-8afc-672db3455e70","internal":{"content":null,"contentDigest":"c20835bef7be9304f3d64a000257591f","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Antiretroviral-naïve subjects who started ART between 1st September 2014 and 30th November 2017 with a DTG-based regimen or others frequently prescribed as first-line. - Virologically suppressed ART experienced individuals switching to a two-drug regimen containing DTG from 1st September 2014 to 30th November 2017. - Subjects aged >=18 years Exclusion Criteria: - Subjects with no follow-up after switching to a two-drug regimen containing DTG - Subjects with no follow-up after initiation of ART","interventions":[],"interventional_subtype":"","is_fda_regulated":false,"is_high_value":false,"is_ind_study":false,"keywords":["Human immunodeficiency virus","CoRIS","Dolutegravir","Antiretroviral therapy"],"last_follow_up_date":"12/16/2019 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"","maximum_age":null,"minimum_age":"18Years","minimum_age_raw":"18Years","modified_date":"10/01/2018 22:48:08","number_of_arms":"0","observational_design":{"biospecimen_description":"","biospecimen_retention":"None retained","number_of_groups":"0","observational_study_design":"Cohort","patient_registry":"false","target_duration_quantity":"","target_duration_units":"","timing":"Retrospective"},"official_title":"Use and effectiveness of dolutegravir-based regimens in naïve and virologically suppressed ART-experienced individuals from the Cohort of the Spanish AIDS Research Network (CoRIS)","org_study_id":"208569","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Recruiting - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 4","primary_compl_date":"12/16/2019 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Number of subjects initiating ART regimen","outcome_time_frame":"Up to 169 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time to treatment modifications after initiation of ART","outcome_time_frame":"Up to 144 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of reasons for treatment modifications after initiation of ART","outcome_time_frame":"Up to 144 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with virological responses after initiation of ART","outcome_time_frame":"Up to 144 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with immunological responses after initiation of ART","outcome_time_frame":"Up to 144 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of reasons for switching to DTG-based dual regimen","outcome_time_frame":"Up to 169 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time to virological failure before switching to DTG-based dual regimen","outcome_time_frame":"Up to 169 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time to treatment modifications after switching to DTG-based dual regimen","outcome_time_frame":"Up to 48 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of reasons for treatment modifications after switching to DTG-based dual regimen","outcome_time_frame":"Up to 48 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with virological responses after switching to DTG-based dual regimen","outcome_time_frame":"Up to 48 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with immunological responses after switching to DTG-based dual regimen","outcome_time_frame":"Up to 48 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time to confirmed virological failure","outcome_time_frame":"Up to 48 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time to virological failure","outcome_time_frame":"Up to 48 weeks","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["Institute Carlos III"]},"start_date":"01/31/2018 00:00:00","study_type":"Observational","therapeutic_area":"","citations":[],"is_section_801":null}},"pageContext":{"studyId":"208569"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}